Cargando…
Identification of biomarker‐by‐treatment interactions in randomized clinical trials with survival outcomes and high‐dimensional spaces
Stratified medicine seeks to identify biomarkers or parsimonious gene signatures distinguishing patients that will benefit most from a targeted treatment. We evaluated 12 approaches in high‐dimensional Cox models in randomized clinical trials: penalization of the biomarker main effects and biomarker...
Autores principales: | Ternès, Nils, Rotolo, Federico, Heinze, Georg, Michiels, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763402/ https://www.ncbi.nlm.nih.gov/pubmed/27862181 http://dx.doi.org/10.1002/bimj.201500234 |
Ejemplares similares
-
Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials
por: Ternès, Nils, et al.
Publicado: (2017) -
Meta‐analysis of two studies in the presence of heterogeneity with applications in rare diseases
por: Friede, Tim, et al.
Publicado: (2016) -
Determination of the optimal sample size for a clinical trial accounting for the population size
por: Stallard, Nigel, et al.
Publicado: (2016) -
Prediction of treatment benefit in high-dimensional cox models via gene signatures in randomized clinical trials
por: Ternès, Nils, et al.
Publicado: (2015) -
Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice
por: Michiels, S., et al.
Publicado: (2016)